PRO-140 Progenies

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

PRO-140, a monoclonal antibody against the HIV coreceptor CCR5, is under investigation by Progenies and the Aaron Diamond AIDS Research Center (ADARC) as a potetitial treatment for HIV infection [211441], [286246], [286247]. Pliase I/II trials were expected to commence during 2001 [395621], [409142], despite being initially planned for 2000 [322637], [361819], [365216], [375598], [408483]. In January 1998, ADARC and Progenies reported that the HIV binding site on the CCR5 coreceptor is distinct from betachemokine binding domains, îvhich they claimed may allow for the development of therapeutics with fewer side effects [273391], [421256]. In vitro studies have shown PRO-140 potently blocked all of 17 primary HIV isolates that use CCR5 as a fusion coreceptor [342173]. In October 2000, Progenies was awarded an SB1R grant to fund a 2-year project exploring the breadth, potency and durability of PRO-140 therapy in laboratory and animal models of HIV infection. This project ivas a collaboration betiveen Progenies, Weill Medical College of Cornell University and the Scripps Research Institute [385982]. In May 1999, the company altered into an agreement itrith Protein Design Labs (PDL) for the humanization by PDL of PRO-140 [325445]. In November 1997, Progenies was awarded a $600,000 grant from the NIAIDfor the examination of new approaches to HIV vaccine design based on CCR5 [268407].

Original languageEnglish
Pages (from-to)1068-1071
Number of pages4
JournalIDrugs
Volume4
Issue number9
Publication statusPublished - 2001

Fingerprint

Diamond
HIV
HIV Infections
Acquired Immunodeficiency Syndrome
AIDS Vaccines
Organized Financing
Financial Management
Research
Proteins
Animal Models
Binding Sites
PRO-140 monoclonal antibody
Therapeutics
In Vitro Techniques

ASJC Scopus subject areas

  • Pharmacology

Cite this

Poli, G. (2001). PRO-140 Progenies. IDrugs, 4(9), 1068-1071.

PRO-140 Progenies. / Poli, Guido.

In: IDrugs, Vol. 4, No. 9, 2001, p. 1068-1071.

Research output: Contribution to journalArticle

Poli, G 2001, 'PRO-140 Progenies', IDrugs, vol. 4, no. 9, pp. 1068-1071.
Poli G. PRO-140 Progenies. IDrugs. 2001;4(9):1068-1071.
Poli, Guido. / PRO-140 Progenies. In: IDrugs. 2001 ; Vol. 4, No. 9. pp. 1068-1071.
@article{63c3c2acd0b44706bf1e86093969590c,
title = "PRO-140 Progenies",
abstract = "PRO-140, a monoclonal antibody against the HIV coreceptor CCR5, is under investigation by Progenies and the Aaron Diamond AIDS Research Center (ADARC) as a potetitial treatment for HIV infection [211441], [286246], [286247]. Pliase I/II trials were expected to commence during 2001 [395621], [409142], despite being initially planned for 2000 [322637], [361819], [365216], [375598], [408483]. In January 1998, ADARC and Progenies reported that the HIV binding site on the CCR5 coreceptor is distinct from betachemokine binding domains, {\^i}vhich they claimed may allow for the development of therapeutics with fewer side effects [273391], [421256]. In vitro studies have shown PRO-140 potently blocked all of 17 primary HIV isolates that use CCR5 as a fusion coreceptor [342173]. In October 2000, Progenies was awarded an SB1R grant to fund a 2-year project exploring the breadth, potency and durability of PRO-140 therapy in laboratory and animal models of HIV infection. This project ivas a collaboration betiveen Progenies, Weill Medical College of Cornell University and the Scripps Research Institute [385982]. In May 1999, the company altered into an agreement itrith Protein Design Labs (PDL) for the humanization by PDL of PRO-140 [325445]. In November 1997, Progenies was awarded a $600,000 grant from the NIAIDfor the examination of new approaches to HIV vaccine design based on CCR5 [268407].",
author = "Guido Poli",
year = "2001",
language = "English",
volume = "4",
pages = "1068--1071",
journal = "IDrugs : the investigational drugs journal",
issn = "1369-7056",
publisher = "Current Drugs Ltd.",
number = "9",

}

TY - JOUR

T1 - PRO-140 Progenies

AU - Poli, Guido

PY - 2001

Y1 - 2001

N2 - PRO-140, a monoclonal antibody against the HIV coreceptor CCR5, is under investigation by Progenies and the Aaron Diamond AIDS Research Center (ADARC) as a potetitial treatment for HIV infection [211441], [286246], [286247]. Pliase I/II trials were expected to commence during 2001 [395621], [409142], despite being initially planned for 2000 [322637], [361819], [365216], [375598], [408483]. In January 1998, ADARC and Progenies reported that the HIV binding site on the CCR5 coreceptor is distinct from betachemokine binding domains, îvhich they claimed may allow for the development of therapeutics with fewer side effects [273391], [421256]. In vitro studies have shown PRO-140 potently blocked all of 17 primary HIV isolates that use CCR5 as a fusion coreceptor [342173]. In October 2000, Progenies was awarded an SB1R grant to fund a 2-year project exploring the breadth, potency and durability of PRO-140 therapy in laboratory and animal models of HIV infection. This project ivas a collaboration betiveen Progenies, Weill Medical College of Cornell University and the Scripps Research Institute [385982]. In May 1999, the company altered into an agreement itrith Protein Design Labs (PDL) for the humanization by PDL of PRO-140 [325445]. In November 1997, Progenies was awarded a $600,000 grant from the NIAIDfor the examination of new approaches to HIV vaccine design based on CCR5 [268407].

AB - PRO-140, a monoclonal antibody against the HIV coreceptor CCR5, is under investigation by Progenies and the Aaron Diamond AIDS Research Center (ADARC) as a potetitial treatment for HIV infection [211441], [286246], [286247]. Pliase I/II trials were expected to commence during 2001 [395621], [409142], despite being initially planned for 2000 [322637], [361819], [365216], [375598], [408483]. In January 1998, ADARC and Progenies reported that the HIV binding site on the CCR5 coreceptor is distinct from betachemokine binding domains, îvhich they claimed may allow for the development of therapeutics with fewer side effects [273391], [421256]. In vitro studies have shown PRO-140 potently blocked all of 17 primary HIV isolates that use CCR5 as a fusion coreceptor [342173]. In October 2000, Progenies was awarded an SB1R grant to fund a 2-year project exploring the breadth, potency and durability of PRO-140 therapy in laboratory and animal models of HIV infection. This project ivas a collaboration betiveen Progenies, Weill Medical College of Cornell University and the Scripps Research Institute [385982]. In May 1999, the company altered into an agreement itrith Protein Design Labs (PDL) for the humanization by PDL of PRO-140 [325445]. In November 1997, Progenies was awarded a $600,000 grant from the NIAIDfor the examination of new approaches to HIV vaccine design based on CCR5 [268407].

UR - http://www.scopus.com/inward/record.url?scp=0042896001&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042896001&partnerID=8YFLogxK

M3 - Article

C2 - 15965853

AN - SCOPUS:0042896001

VL - 4

SP - 1068

EP - 1071

JO - IDrugs : the investigational drugs journal

JF - IDrugs : the investigational drugs journal

SN - 1369-7056

IS - 9

ER -